Colorectal Cancer

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

The phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer will be discontinued due to futility.

Cathy Eng, M, FACP, FASCO, presents a comprehensive End-of-Year Review in Colorectal Cancer (CRC), delving into the exploration of emerging treatment options and clinical insights on the future landscape. This insightful review includes a focus on the recent approval of fruquintinib and important updates on target therapies for HER2+, BRAF V600E-Mutant, and KRAS-mutant CRC, as well as an interactive Q&A segment.

The combination of nivolumab and ipilimumab led to a statistically significant and clinically meaningful improvement in progression-free survival per blinded independent central review compared with investigator’s choice of chemotherapy as frontline therapy in patients with metastatic colorectal cancer.

The triplet combination of sintilimab, chidamide, and bevacizumab resulted in a high 18-week progression-free survival rate with a favorable toxicity profile in patients with microsatellite stable or mismatch repair–proficient metastatic colorectal cancer, according to data from the phase 2 CAPability-01 trial.

Pembrolizumab continued to demonstrate at trend toward improved overall survival compared with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

SCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) prolonged survival in heavily pretreated patients with metastatic colorectal cancer who had no other active treatment options available, according to final data from part 2 of the phase 2 CORIST study.

John Lindsay Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

The FDA has approved fruquintinib (Fruzaqla) for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

The addition of panitumumab to FOLFIRINOX or mFOLFOX6 led to comparable overall response rates and complete response rates in patients with RAS or BRAF V600E wild-type, unresectable, metastatic colorectal cancer without liver-limited disease.

The combination of garsorasib and cetuximab elicited responses and was found to be well tolerated in heavily pretreated patients with KRAS G12C–mutated colorectal cancer.

Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

Filippo Pietrantonio, MD, discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.

David S. Hong, MD, discusses preliminary efficacy data from a phase 1 trial f the KRAS G12C inhibitor RMC-6291 in advanced KRAS G12C–mutant solid tumors.

David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.

The novel mRNA biomarkers in the noninvasive ColoAlert® screening test displayed sensitivity and specificity for detecting colorectal cancer and advanced adenomas that could be precursors to CRC.

The FDA has approved the CRCdx® RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer, according to an announcement from EntroGen.

A new drug application seeking the approval of fruquintinib for the treatment of adult patients with previously treated metastatic colorectal cancer has been submitted to Japan’s Ministry of Health, Labour, and Welfare.

Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.

Circulating tumor DNA status at the time of postoperative minimal residual disease is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer

Although findings from the International Duration Evaluation of Adjuvant Therapy collaboration in 2018 failed to demonstrate the noninferiority of 3 months of adjuvant chemotherapy vs 6 months for patients with stage III colon cancer, clinically relevant data in subgroup analyses have influenced practice prescribing patterns, according to a retrospective analysis.

The integration of novel mRNA biomarkers into the ColoAlert® screening test resulted in high sensitivity and specificity for colorectal cancer.